Type:250ml bot
Generic Name:Moxifloxacin IV
Manufacturer:Square Pharmaceuticals PLC.
Price:৳350.00
Community Acquired Pneumonia, Acute Bacterial Exacerbation of Chronic Bronchitis, Acute Bacterial Sinusitis, Complicated Intra-Abdominal Infection, Uncomplicated Skin and Skin Structure Infections, Complicated Skin and Skin Structure Infections, Typhoid Fever.
IV Preparation No further dilution of infusion solution is necessary IV Administration Infuse over 1 hour
Moxifloxacin 400 mg IV infusion can be administered intravenously once daily for 5-21 days, depending on the condition. The duration of therapy depends on the type of infection as described bellow- Intravenous Acute bacterial sinusitis Adult: 400 mg once daily infused over 60 min for 10 days. Acute bacterial exacerbation of chronic bronchitis Adult: 400 mg once daily infused over 60 min for 5 days. Community-acquired pneumonia Adult: 400 mg once daily infused over 60 min for 7-14 days. Skin and skin structure infections Adult: Complicated: 400 mg once daily for 7-21 days; uncomplicated: 400 mg once daily for 7 days. Doses to be infused over 60 min. Intra-abdominal infections Adult: 400 mg once daily infused over 60 min for 5-14 days. May change to oral therapy when clinically appropriate. Elderly: No adjustment of dosage is required in the elderly.
<18 years: Safety and efficacy not established
Known hypersensitivity to moxifloxacin, other quinolones. Patients w/ known prolongation of QT interval, uncorrected hypokalaemia, myasthenia gravis. Concurrent use of class Ia (e.g.quinidine, procainamide, class III (e.g. amiodarone, sotalol) antiarrhythmic drugs or w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents).
Moxifloxacin inhibits the topoisomerase II (DNA gyrase) and topoisomerase IV required for bacterial DNA replication, transcription, repair and recombination.
Maintain adequate fluid intake; Patient w/ previous tendon disorders (e.g. rheumatoid arthritis), significant bradycardia or acute myocardial ischaemia, heart failure w/ reduced LVEF, known history of symptomatic arrhythmias, known or suspected CNS disorders (e.g. severe cerebral arteriosclerosis, epilepsy) or other risk factors that predispose to seizures; diabetes. Kidney, heart or lung transplant recipients. Hepatic impairment. Pregnancy and lactation. Patient Counselling This drug may cause dizziness and lightheadedness, if affected do not drive or operate machinery. Rest and refrain from doing strenuous physical activity as it may increase risk of tendon rupture. Avoid exposure to sunlight or artificial UV light (e.g. tanning beds, UVA/UVB treatment) and use protective measures (e.g. sunscreen, wear loose-fitting clothes) if staying outdoors is necessary during therapy. Monitoring Parameters Monitor WBC and signs of infection.
1-10% Nausea (7%),Diarrhea (6%),Dizziness (3%),Decreased amylase (2%),Decreased basophils, eosinophils, hemoglobin, prothrombin time, red blood cells, neutrophils (2%),Decreased serum glucose (2%),Increased serum chloride (2%),Increased serum ionized calcium (2%),Immune hypersensitivity reaction (0.1-2%),Prolonged QT interval (0.1-2%) <1% Acute renal failure,Agranulocytosis,Anaphylactoid reaction,Aplastic anemia,Extrinsic allergic alveolitis,Hemolytic anemia,Hepatic failure,Hepatic necrosis,Hepatitis,Pancytopenia,Seizure,Serum sickness due to drug,Stevens-Johnson syndrome,Tendon rupture, tendinitis,Thrombocytopenia,Torsades de pointes,Toxic epidermal necrolysis
Additive effect on QT interval prolongation w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents). Decreased absorption and bioavailability w/ Al- or Mg-containing antacids, or Fe or Zn preparations. Concomitant use of corticosteroids increases the risk of severe tendon disorders esp in elderly (>60 yr). Decreased absorption w/ sucralfate or didanosine. Potentially Fatal: Concurrent use of class Ia (e.g. quinidine, procainamide) or III (e.g. amiodarone, sotalol) antiarrhythmic drugs or w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents) may cause additive effect on QT interval prolongation.
